American journal of respiratory and critical care medicine · 2026
Extracorporeal life support in adult critically ill patients: mechanisms of benefit in respiratory and cardiac failure.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zochios Vasileios, Brewer Joseph M, Antonini Marta Velia, Brodie Daniel, Peek Giles J, Schmidt Matthieu, Camporota Luigi, Doyle James, Tschernko Edda, Schultz Marcus J, Yusuff Hakeem, Endorsing Societies of College of Intensive Care Medicine (CICM) UK; Pulmonary Vascular Research Institute (PVRI); Protective Ventilation Network (PROVE Network); Association for Cardiothoracic Anaesthesia and Critical Care (ACTACC); Society of Mechanical Ventilation (SMV); Protecting the Right Ventricle Network (PRORVnet)
Аннотация
Extracorporeal life support provides temporary cardiorespiratory support for patients with severe, potentially reversible cardiac and/or respiratory failure refractory to conventional measures. Its application has broadened across a wide spectrum of critical illness, yet the mechanistic basis of its physiologic benefit remains incompletely defined. This review explores the mechanisms through which extracorporeal life support may confer benefit in respiratory and cardiac failure. These include restoration of gas exchange, optimization of circulatory dynamics, and mitigation of secondary organ injuries, creating conditions that facilitate tissue repair, enable adjunctive therapies, and, in selected cases, provide a bridge to transplantation. In isolated respiratory failure, respiratory extracorporeal life support stabilizes gas exchange and modulates respiratory drive, enabling lung-protective ventilation and potentially attenuating ventilator- and patient self-inflicted lung injury. In cardiogenic shock, cardiac extracorporeal life support restores systemic perfusion and may reduce myocardial oxygen demand, while during cardiac arrest, it may confer neuroprotective effects. In combined cardiorespiratory failure, advanced extracorporeal support modalities may augment both systemic and pulmonary circulation, supporting gas exchange and maintaining end-organ perfusion. Mechanistically, these interventions interrupt the cascade of hypoxemia- and/or hypercapnia- induced pulmonary vasoconstriction, right ventricular overload, and systemic hypoperfusion, facilitating multiorgan recovery. Optimizing patient selection, timing for extracorporeal life support initiation, and use of adjunctive therapies require a nuanced understanding of the interplay between these physiologic pathways alongside careful considerations of key limitations, including device-related complications, hematologic and inflammatory perturbations, and physiologic trade-offs. This State-of-the-Art review synthesizes the current literature on the mechanistic basis of extracorporeal life support in adults.